Ajay Madan - 07 Feb 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Development Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
07 Feb 2022
Net transactions value
-$239,085
Form type
4
Filing time
09 Feb 2022, 16:00:20 UTC
Previous filing
04 Feb 2022
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale $239,085 -13,411 -7.2% $17.83 172,045 07 Feb 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $17.170 and $18.015. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.